Benzinga
Benzinga
Benzinga
miércoles, septiembre 16

Acurx Pharmaceuticals Inc

ACXPNASDAQ
Trade with Public
Trade with Public
$1.35
-0.035-2.52%
al cierre: Sep 15, 5:00 PM EST
$1.37
0.0151.11%
After hour: 5:32 PM EST
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadCompararInforme de acciones

Acurx Pharmaceuticals Financials

Acurx Pharmaceuticals (ACXP) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Acurx Pharmaceuticals Q2 EPS $(0.53) Misses $(0.37) Estimate

Acurx Pharmaceuticals (NASDAQ:ACXP) reported quarterly losses of $(0.53) per share which missed the analyst consensus estimate of $(0.37) by 43.24 percent. This is a 71.96 percent increase over losses of $(1.89) per
Benzinga Newsdesk

What's Going On With Acurx Pharmaceuticals Stock Today?

Acurx Pharmaceuticals (NASDAQ:ACXP) shares down on Friday after reporting net loss for Q4 2025, but with positive cash and $1.5M raised.
Nabaparna Bhattacharya

Earnings Scheduled For March 13, 2026

Benzinga Insights

PRO
Acurx Pharmaceuticals Q4 EPS $(0.73) Beats $(1.65) Estimate

Acurx Pharmaceuticals (NASDAQ:ACXP) reported quarterly losses of $(0.73) per share which beat the analyst consensus estimate of $(1.65) by 55.62 percent. This is a 78.53 percent increase over losses of $(3.40) per share
Benzinga Newsdesk

PRO
Acurx Pharmaceuticals Q3 EPS $(1.23) Beats $(1.31) Estimate

Acurx Pharmaceuticals (NASDAQ:ACXP) reported quarterly losses of $(1.23) per share which beat the analyst consensus estimate of $(1.31) by 6.11 percent. This is a 64.35 percent increase over losses of $(3.45) per share
Benzinga Newsdesk

Earnings Scheduled For November 12, 2025

Benzinga Insights

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved